Hereditary breast cancer: Practical pursuit for clinical translation

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 1723-1731

  Lynch, Henry T ^a   Snyder, Carrie ^a   Lynch, Jane ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53;

CANCER CONTROL; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CANCER SUSCEPTIBILITY; DNA DETERMINATION; DNA REPAIR; EMOTIONAL STRESS; FAMILIAL CANCER; FAMILY HISTORY; FAMILY INFORMATION SERVICE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; HEALTH INSURANCE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; MASTECTOMY; MEDICAL INFORMATION SYSTEM; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84865145383     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2256-z     Document Type: Review

References (42)

1. International Agency for Research on Cancer. Globocan 2008. http://www-dep.iarc.fr/.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2010;318: 1108-13. (Pubitemid 350134889)
4. Lin J, Gan CM, Zhang X, et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res. 2010;17:1304-18. (Pubitemid 47360905)
5. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2010; 314:268-74. (Pubitemid 44571966)
6. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870-4. (Pubitemid 47014500)
7. Easton DF, Pooley KA, Dunning AM, et al.; the SEARCH Collaborators. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087-93. (Pubitemid 47014426)
8. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003;21:740-53. (Pubitemid 46621912)
9. Guttmacher AE, Collins FS, Carmona RH. The family history-more important than ever. N Engl J Med. 2004;351:2333-6. (Pubitemid 39552752)
10. Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch PM. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol. 2007;25: 3534-42. (Pubitemid 47310892)
11. Lynch HT, Marcus JN, Lynch J, Snyder CL, Rubinstein WS. Breast cancer genetics: syndromes, genes, pathology, counseling, testing, and treatment. In: Bland KI, Copeland EM III, editors. The breast: comprehensive management of benign and malignant disorders. 4th ed. Philadelphia, PA: Saunders; 2009. p 371-415.
12. Watson P, Narod SA, Fodde R, et al. Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colo-rectal cancer and hereditary breast-ovarian cancer. J Hum Genet. 2003;40:591-6. (Pubitemid 37046912)
13. Lynch HT, Marcus JN, Watson P, Lynch J. Familial breast cancer, cancer family syndromes, and predisposition to breast neoplasms. In: Bland K, Copeland EM, editors. The breast. Philadelphia: Saunders; 1991. p. 262-91.
14. Marcus J, Watson P, Linder-Stephenson L, Conway T, Page D, Lynch H. The pathobiology of BRCA1-linked and-unlinked hereditary breast cancer (HBC) (abstract). Mod Pathol. 1994; 7:18A.
15. Claus EB, Risch N, Thompson WD, et al. Relationship between breast histopathology and family history of breast cancer. Am J Epidemiol. 1990;131:961-72.
16. Marcus J, Page D, Watson P, Conway T, Lynch H. High mitotic grade in hereditary breast cancer (abstract). Lab Invest. 1988; 56:61A.
17. Rosen PP, Lesser ML, Senie MA, Kinne DW. Epidemiology of breast carcinoma III: relationship of family history to tumor type. Cancer. 1982;50:171-9. (Pubitemid 12084873)
18. Erdreich LS, Asal NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. Southern Med J. 1980;73:28-32. (Pubitemid 10146187)
19. LiVolsi VA, Kelsey JL, Fischer DB, Holford TR, Mostow ED, Goldenberg IS. Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. Cancer. 1982;49:1937-40. (Pubitemid 12153469)
20. Stalsberg H, Thomas DB, Noonan EA. The WHO collaborative study of neoplasia and steroid contraceptives. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Cancer. 1989;44:399-409. (Pubitemid 19229294)
21. Lagios MD, Rose MR, Margolin FR. Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol. 1980;73: 25-30. (Pubitemid 10180390)
22. Mosimann S, Torhorst JKH, Weber W, Muller H. Histopatholo-gical aspects of familial breast cancer. In: Weber W, Laffer UT, Durig M, editors. Hereditary cancer and preventive surgery. Karger: Basel; 1990. p 1-7.
23. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer. 1993;71:147-53. (Pubitemid 23019295)
24. Glebov OK, McKenzie KE, White CA, Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 1994;54:3703-9. (Pubitemid 24241183)
25. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangi-ectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749-53.
26. Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010;16:48-52.
27. Drew Y, Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol. 2010;22:67-71.
28. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009;27:18s (suppl; abstr 3).
29. Hall MJ, Reid JE, Burbridge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-33.
30. Mangold KA, Wang V, Weissman SM, Rubinstein WS, Kaul KL. Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences. J Mol Diagn. 2010;12:20-6.
31. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-88.
32. Díez O, Osorio A, Durán M, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat. 2003;22:301-12. (Pubitemid 37210855)
33. Huusko P, Juo SH, Gillanders E, et al. Genome-wide scanning for linkage in Finnish breast cancer families. Eur J Hum Genet. 2004;12:98-104. (Pubitemid 38263553)
34. Smith P, McGuffog L, Easton DF, et al. A genome wide linkage search for breast cancer susuceptibility genes. Genes Chromosomes Cancer. 2006;45:646-55. (Pubitemid 43727152)
35. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362:986-93.
36. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-7. (Pubitemid 33094870)
37. Rebbeck TR, Lynch HT, Neuhausen SL, et al., for The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-22.
38. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055-62. (Pubitemid 41095038)
39. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-75.
40. Lynch HT. Family information service and hereditary cancer. Cancer. 2001;91:625-8. (Pubitemid 32173284)
41. Lynch HT, Snyder C, Lynch J, Ghate S, Thome S. Family information service (FIS) in a BRCA1 extended family (abstract). J Clin Oncol. 2006;24:55s.
42. MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw. 2010;8:615-24.